PDCD1 and classic Hodgkin lymphoma: Recently, the KEYNOTE‐204 study demonstrated a significant progression‐free survival advantage for relapsed cHL patients treated with pembrolizumab, a PD1 inhibitor, over the anti‐CD30‐conjugated antibody brentuximab vedotin (BV).7